Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Gynecologic 1

Conditions

Uterine Cervical Neoplasms 2Uterine Neoplasms 1Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Endometrial Neoplasms 1

Interventions

pembrolizumab 14Specimen Handling 8Docetaxel 8olaparib 7Nivolumab 7Gemcitabine 7Trastuzumab 6Paclitaxel 6rucaparib 5Magnetic Resonance Spectroscopy 5Early Intervention, Educational 5Biopsy 5Standard of Care 4Cyclophosphamide 4Carboplatin 4tisotumab vedotin 3talazoparib 3pertuzumab 3durvalumab 3atezolizumab 3Taxes 3Surveys and Questionnaires 3Sirolimus 3Radiotherapy 3Psychiatric Rehabilitation 3Methods 3Irinotecan 3Immunoglobulin G 3Fulvestrant 3Educational Status 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostatic Neoplasms × ferumoxtran-10 × Gynecologic × Clear all
NCT00188695 2022-10-07

Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide

University Health Network, Toronto

Phase 1/2 Completed
61 enrolled
GenitourinaryGynecologic

Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Prostatic Neoplasms, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡